Publications database

This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole (5-IT), that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability...

This publication presents the summary findings and the conclusions of the risk assessment on mephedrone, carried out by the EMCDDA’s extended Scientific Committee, with participation of additional experts from the European Commission...

The risk-assessment reports on the synthetic drugs 2C-I; 2C-T-2 and 2C-T-7 were submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The reports were drawn up at...

The risk-assessment report on the synthetic drug TMA-2 was submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The report was drawn up at a meeting in...

The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in...

Since the mid-1990s, GHB – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Some EU countries have reported worries over GHB’s surreptitious...

Since the mid-1990s, ketamine – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Concern over ketamine centres on its unpredictability in producing...

On 27 February 1998, the drug MBDB (N-methyl-1-(1,3-benzodioxol- 5-yl)-2-butanamine) became the first new synthetic drug to be submitted for risk assessment under the terms of the Joint Action concerning the information exchange...